Search the Newsreel

Moody's Corp. stock underperforms Thursday when compared to competitors despite daily gains

Shares of Moody's Corp. (MCO) rallied 2.21% on Thursday, despite underperforming compared to its competitors. This gain occurred during a strong trading session for the broader market, with the S&P 500 and Dow Jones Industrial Average also posting increases. This marks the second consecutive …

Odysight.ai Inc. (ODYS) posts $9.5M loss and $17.6M cash in H1 2026

Odysight.ai Inc. reported a significant revenue drop and widening losses for the first half of 2026, primarily due to the loss of a major Fortune 500 medical customer. Despite this, the company maintained $17.6 million in cash and cash equivalents, and its backlog and …

Odysight.ai reports H1 2026: $0.5M revenue, $9.5M net loss, $17.6M cash and $16.45M backlog

Odysight.ai reported H1 2026 revenues of $0.5 million and a net loss of $9.5 million. The company maintained approximately $17.6 million in cash and reported a backlog of $16.45 million, with management anticipating revenue to be weighted towards the second half of 2026. Key …

Odysight.ai Inc. Q2 2026: Revenue $420K, EPS ($0.26) — 10-Q Summary

Odysight.ai Inc. reported Q2 2026 revenues of $420K, a 16% increase year-over-year, despite a net loss of ($4.32M) and a diluted loss per share of ($0.26). The company highlighted sequential improvement in revenue, significant market momentum from Nasdaq and TASE listings, and a backlog …

Odysight.ai (ODYS) revenue drops as backlog grows and Boeing order arrives

Odysight.ai reported a significant revenue drop in the first half of 2026 to $0.5 million, down from $2.4 million a year prior, leading to a widened net loss of $9.5 million. Despite this, the company's backlog grew to approximately $16.45 million, supported by new …

Odysight.ai Reports $0.5 Million First-Half Revenue and $16.45 Million Backlog

Odysight.ai Reports Financial Results for the First Half of 2026 and Provides Business Update

Odysight.ai Inc. Ramat Gan, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ/TASE: ODYS), a leader in AI-powered visual sensing and predictive maintenance (PdM) solutions for the aerospace, defense, and industrial markets, today announces its financial results for the first half of 2026, …

Odysight.ai signs agreement with Boeing to demonstrate AI-Powered capabilities

Odysight.ai Inc. The agreement will showcase vision-based technology at two Boeing sites in laboratory and test environments Ramat Gan, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ/TASE: ODYS), a leader in AI‑powered visual sensing and predictive maintenance (PdM) solutions for the aerospace, …

Moody's Corporation (MCO) Appoints Keith Demmings to Board of Directors

Moody's Corporation (MCO) has announced the appointment of Keith Demmings, the current President and CEO of Assurant, Inc., to its Board of Directors, effective November 1, 2026. Demmings brings nearly three decades of experience leading global businesses and will receive an annual cash retainer …

Moodys Stock And 2 Bond Market Plays If CPI Shifts Rate Cut Expectations

This article discusses three companies—BGC Group, Moody's, and Artisan Partners Asset Management—that are particularly exposed to shifts in interest rate expectations, especially following the upcoming July CPI report. These companies offer various ways for investors to gain exposure to the bond market, from brokerage …

Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026

This article provides an overview of Odyssey Therapeutics (ODTX) stock trends and sentiment as of August 2026. It highlights recent media mentions, MarketBeat follower growth, search trends, and page views, indicating increasing interest in the company. The page also presents current stock price and …

Odysight.ai Inc. Common Stock (NASDAQ: ODYS) Share Price, ODYS Stock News, ODYS Share Price & Updates

This page provides current stock information for Odysight.ai Inc. (NASDAQ: ODYS), including its real-time share price, daily range, and recent news. It also lists key financial fundamentals, upcoming events like conference participations, and links to financial reports such as quarterly and full-year results.

Odysight.ai to Participate in Upcoming Investor Conferences

Odysight.ai Inc., a company specializing in AI-powered visual sensing and predictive maintenance, announced its participation in two upcoming investor conferences. CEO Yehu Ofer and CFO Einav Brenner will present at the Sidoti Virtual Micro-Cap Conference in August 2026, and CFO Einav Brenner will attend …

J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29

J.P. Morgan has reiterated its Buy rating on Odyssey Therapeutics (ODTX.US) and increased its target price for the company's stock to $29. This adjustment reflects a continued positive outlook from the financial institution regarding Odyssey Therapeutics' future performance.

Odysight.ai CEO and CFO set for two Q3 presentations

Odysight.ai (NASDAQ/TASE: ODYS) announced that its CEO, Yehu Ofer, and CFO, Einav Brenner, will participate in two investor conferences in Q3 2026. They will present virtually at the Sidoti Virtual Micro-Cap Conference on August 20, 2026, and the CFO will also present at the …

Moody's (MCO) Faces Private Credit Risk, Is The Stock Already Fully Valued?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Mounting risks in private credit, especially weaker recoveries on software loans flagged by SLR Capital Partners, have pushed investors to reassess how Moody's …

ODYSSEY MARINE EXPLORATION INC 2Q 2026: Revenue $77.9K, EPS $(0.16) — 10-Q Summary

ODYSSEY MARINE EXPLORATION INC (OMEX) reported its second-quarter 2026 results, showing revenue of $77.9K and a diluted loss per share of $(0.16). While revenue decreased by 42.2% year-over-year, the net loss improved from $(14.85M) to $(9.31M). Key business highlights include a pending merger with …

Odyssey Marine Exploration (OMEX) details deep Q2 loss and $900M AOM merger plan

Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands

Odyssey Therapeutics (ODTX) stock has seen a 28.9% increase year-to-date, fueled by an AI-enabled research partnership with Evotec. Despite this, the company's valuation checks suggest it is not a clear bargain, trading at a price-to-book ratio of about 2.4x, which is in line with …

Moody's Corporation (NYSE:MCO) Given Average Rating of "Moderate Buy" by Analysts

Twenty brokerages have assigned Moody's Corporation (NYSE:MCO) an average "Moderate Buy" rating, with a consensus 12-month price target of $553.61. The company recently exceeded quarterly expectations, reporting adjusted EPS of $4.68 and a 15.1% increase in revenue, and has issued fiscal 2026 EPS guidance …

Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger …

Why You Might Be Interested In Moody's Corporation (NYSE:MCO) For Its Upcoming Dividend

Moody's Corporation (NYSE:MCO) is set to pay a dividend of $0.85 per share on September 12, 2024, with the ex-dividend date on August 22, 2024. While the dividend yield of 0.8% is relatively low, the company has a strong history of dividend growth and …

Top Odyssey Therapeutics (ODTX) Competitors 2026

This article analyzes Odyssey Therapeutics (ODTX) against five of its biotechnology competitors: Relay Therapeutics (RLAY), Alumis (ALMS), Arcus Biosciences (RCUS), Legend Biotech (LEGN), and Telix Pharmaceuticals (TLX). MarketBeat compares these companies based on various financial metrics, analyst ratings, profitability, and media sentiment to help …

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Sarasin & Partners LLP Sells 141,999 Shares of Moody's Corporation $MCO

Sarasin & Partners LLP significantly reduced its stake in Moody's Corporation (NYSE:MCO) by 49.3% in the second quarter, selling 141,999 shares but still retaining a substantial holding. Despite this sale, analysts maintain a "Moderate Buy" rating for Moody's with a consensus price target of …

Odysight.AI Inc (ODYS) Stock News Today

This article provides current stock information for Odysight.AI Inc (ODYS) on TradingKey. It displays the stock's market performance, including its closing price, market cap, and links to various financial data sections. The page indicates that more news and updates for ODYS will be available …

Odysight.AI Inc (ODYS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Odysight.AI Inc (ODYS), highlighting its current earnings forecast score of 8.00 and an average price target of $10.00. Based on one analyst, the stock has a "Buy" rating with a potential upside of 36.36%. The company's expected …

Moody's Corporation $MCO Stock Holdings Lifted by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly increased its stake in Moody's Corporation (NYSE:MCO) by 156.5% during the second quarter, now owning 133,743 shares valued at $60.58 million. Other institutional investors also adjusted their holdings, and various Wall Street analysts have issued "Buy" or "Hold" ratings …

ETFs Investing in Moody's Corporation Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Moody's Corporation (MCO) stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover a range of investment strategies, including passive total …

Odyssey Marine Exploration Inc (OMEX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Odyssey Marine Exploration Inc (OMEX), noting that no earnings forecast score is currently available for the company, while the industry average is 7.63. It also includes the latest stock price, market capitalization, and a comparison with peer …

Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has increased its price target for Odyssey Therapeutics (NASDAQ:ODTX) to $29.00 from $26.00, maintaining an "overweight" rating and suggesting a potential upside of 32.12%. This positive outlook is supported by a "Moderate Buy" consensus rating from analysts and recent insider …

Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary

Odyssey Therapeutics, Inc. reported Q2 2026 results, showing $0 revenue and a net loss of $52.8M, or $(1.74) EPS. The company noted a shift from collaboration revenue and stated that proceeds from its IPO and a private placement extend its cash runway into the …

Moody's Corp. stock underperforms Thursday when compared to competitors

Moody's Corp. (MCO) shares fell by 2.24% on Thursday, closing at $473.13, breaking a three-day winning streak. This underperformance occurred during a generally difficult trading day, with both the S&P 500 Index and the Dow Jones Industrial Average also declining.